Story perspectives

Revolutionary Treatments Surge for Myotonic Dystrophy and Fabry Disease

2/25/2025

33 7

Summary

PepGen Advances DM1 Treatment

PepGen's PGN-EDODM1 is making waves in the fight against myotonic dystrophy type 1 (DM1), boasting a remarkable 29.1% splicing correction in early trials, far surpassing current treatments. At the same time, Protalix Biotherapeutics is on the rise with its promising Fabry disease treatment, Elfabrio, and aims to broaden its pipeline, signaling a bright future for rare disease therapies.

Summary

Mirum Approves CTX Treatment

The FDA has made a groundbreaking decision by approving Ctexli (chenodiol) as the first-ever treatment for cerebrotendinous xanthomatosis (CTX), a rare and challenging lipid storage disease. Developed by Mirum Pharmaceuticals, this innovative therapy targets enzyme deficiencies that lead to cholesterol accumulation. In a promising 24-week trial, patients experienced significant reductions in harmful metabolites, bringing renewed hope to those battling CTX in the U.S., though liver toxicity warnings will require careful monitoring.

1 of 2

PepGen Advances DM1 Treatment

PepGen's PGN-EDODM1 is making waves in the fight against myotonic dystrophy type 1 (DM1), boasting a remarkable 29.1% splicing correction in early trials, far surpassing current treatments. At the same time, Protalix Biotherapeutics is on the rise with its promising Fabry disease treatment, Elfabrio, and aims to broaden its pipeline, signaling a bright future for rare disease therapies.

1 / 2